ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1964

A Role for Microbiota in the Pathophysiology of Takayasu Arteritis (TAK) and Giant Cell Arteritis (GCA)

Anne Desbois1, Dragos Ciocan 2, David Saadoun 1, Gabriel Perlemuter 3 and Patrice Cacoub 4, 1GHPS, Paris, France, 2Hôpital Antoine Beclere, Clamart, France, 3Hôpital Clamart, Paris, France, 4AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Department of Internal Medicine and Clinical Immunology, F-75013, Paris, France, Paris, France

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: giant cell arteritis and microbiome, large vessel vasculitis, Takayasu arteritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 12, 2019

Title: Genetics, Genomics & Proteomics Poster

Session Type: Poster Session (Tuesday)

Session Time: 9:00AM-11:00AM

Background/Purpose: The pathogenesis of Large Vessel Vasculitis (LVV) is not well understood. There is increasing evidence of a close link between intestinal dysbiosis and systemic inflammatory/autoimmune diseases. Gut microbiota has never been studied in LVV. We aimed at comparing the blood microbiota profile of patients with LVV (TAK or GCA) and healthy donors (HD).

Methods: We studied the blood microbiome profile microbiota of 20 patients with TAK, 11 with GCA and 16 HD. The microbiome profile microbiota was assessed by sequencing of the 16S rDNA blood bacterial DNA. Linear Discriminant Analysis (LDA) coupled with effect size measurement (LEfSe) was used to analyse the differences in the microbiome profile between groups.

Results: TAK and GCA patients had a mean age of 45 (23.1; 70.6) and 74.5 (58; 84) years, and were of female gender in 55% and 85%, respectively. Among TAK patients 10 had an active disease and 10 were inactive; among GCA patients, 6 were active and 4 inactive. TAK patients compared to HD showed a specific blood microbiota profile with a significant higher level of the phyla Clostridia (Clostridium saudiense), Cytophagia (Pseudarcella Hirudinis) and Delta-proteobacteria (Bdellovibrio bacteriovorus particularly), whereas Bacillus and Staphylococcus were significantly more abundant in HD (p< 0.05) (Figure). Active compared to inactive TAK patients had significantly lower levels of Staphylococcus. TAK microbiota compared to GCA showed significant higher levels of Bacteroidia (LDA >2; p< 0.05). In TAK patients, differences in the blood microbiome were also associated with a shift of metabolic functions. TAK patients compared to HD showed a significant increase of porphyrin and chlorophyll pathways. Active compared to inactive TAK patients showed increase of the same pathways. GCA patients did not show a specific blood microbiota profile compared to HD, except for lower levels of Bacteroidia.

Conclusion: patients with TAK showed a specific blood microbiome profile as compared to healthy controls and GCA patients. Among TAK patients, significant changes of blood microbiome profile were found in active as compared to inactive patients, and it was associated with specific metabolic functions. 

Microbiome profile of TAK patients compared to HD


Disclosure: A. Desbois, None; D. Ciocan, None; D. Saadoun, None; G. Perlemuter, None; P. Cacoub, Abbvie, 5, AstraZeneca, 5, Bristol meyer squibb, 5, Gilead, 5, Glaxo Smith Kline, 5, Janssen, 5, Merck Sharp Dohme, 5, Roche, 5, Servier, 5, Vifor, 5.

To cite this abstract in AMA style:

Desbois A, Ciocan D, Saadoun D, Perlemuter G, Cacoub P. A Role for Microbiota in the Pathophysiology of Takayasu Arteritis (TAK) and Giant Cell Arteritis (GCA) [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/a-role-for-microbiota-in-the-pathophysiology-of-takayasu-arteritis-tak-and-giant-cell-arteritis-gca/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/a-role-for-microbiota-in-the-pathophysiology-of-takayasu-arteritis-tak-and-giant-cell-arteritis-gca/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology